Latest Headlines

Latest Headlines

Agennix slashes staff in wake of PhIII cancer drug disaster

A few weeks ago Agennix was blitzed after the late-stage failure of its lead program raised questions about its ability to soldier on. Today the German biotech responded, closing a Houston office as the developer cut more than half its staff.

Agennix craters after failed PhIII study of lung cancer drug

German biotech Agennix lost most of its market value after revealing Monday that its most advanced compound fared worse than placebo in a late-stage trial for treating non-small cell lung cancer. And Phase III fiasco has put the future existence of the operation in question, Bloomberg reports.

Agennix raises $13M for late-stage cancer trial

Agennix has raised $13 million in a private placement with existing shareholders. This is the first step of a plan to refinance the company. "The funds we have raised will enable us to continue

Italy's Cosmo to snap up BioXell in $41M deal

Faced with the fallout from a failed trial of its lead therapy, BioXell is following a familiar path taken by a lineup of European developers, agreeing to a buyout offer and joining forces with a

GPC, Agennix get $20M to fuel merger

Germany's GPC Biotech AG and Houston-based Agennix are planning to merge their oncology pipelines. In the deal, GPC is being merged into a new company which will have all of Agennix's shares along